Regulus Therapeutics Inc Share Price

NASDAQ: RGLS

$8.18

+0.04

(+0.43%)

as on June 25, 2025 at 1:29 am IST

$₹

The stock has been delisted from the stock exchange on 24 Jun 2025

Regulus Therapeutics Inc Stock Performance

as on June 25, 2025 at 1:29 am IST

$8.18
Day's Price Range
$8.18
$8.18
52 Week's Low
52 Week's High
$0.83
52-Week Price Range
$8.35
$8.18
89.85%
Downside
2.02%
Upside

Regulus Therapeutics Inc share price movements today

Previous Close: $8.14
Open: $8.18
Volume: 801.0
Day's Low - High: $8.18 - $8.18
52 Week Low - High: $0.83 - $8.35

Regulus Therapeutics Inc Historical Returns

1 Month Return: 0 %
3 Month Return: 0 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Regulus Therapeutics Inc Stock Fundamentals & Key Indicators

Check Regulus Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

EPS (TTM)

Dividend Yield

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

Return On Equity TTM

0.00%

Regulus Therapeutics Inc stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Regulus Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Regulus Therapeutics Inc	BUY	$-	NA	NA	0.00%

Analyst Recommendation on Regulus Therapeutics Inc Stock

Based on 10 analysts

BUY

80.00%

Buy

20.00%

Hold

0.00%

Sell

Based on 10 analysts, 80% of analysts recommend a 'BUY' rating for Regulus Therapeutics Inc. Average target price of $8.8

Regulus Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Regulus Therapeutics Inc.

What analysts predicted

7.05%UPSIDE

Target Price

$8.8

Current Price

$8.18

Analyzed by

10 Analysts

Target

$8.80

Regulus Therapeutics Inc target price $8.8, a slight upside of 7.05% compared to current price of $8.18. According to 10 analysts rating.

Regulus Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Total Revenue	-	-	-	-	0	-	-	-	-	0
Gross Profit	0	0	0	0	0	0	0	-	-	0
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-6	-7	-7	-7	-8	-8	-11	-14	-12	-9
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-2669.21%	0.00%	0.00%	0.00%	0.00%	-2833.53%

Regulus Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	20	1	0	0	6	10	0	-	-	-
Gross Profit	-35	-63	-54	0	6	10	0	0	-21	-
Operating Income	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-	-	-	-	-	-	-	-	-	-
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-55	-81	-71	-48	-18	-15	-27	-28	-30	-46
Net Profit Margin	-268.55%	-6853.94%	-99868.06%	-67651.39%	-272.13%	-152.54%	-277469.57%	0.00%	0.00%	0.00%

Global Institutional Holdings in Regulus Therapeutics Inc

Funds	Holdings
Federated Hermes Inc	22.85%
NEA Management Company, LLC	9.34%
Octagon Capital Advisors LP	6.7%
BlackRock Inc	6.02%
Vanguard Group Inc	5.71%

See all

About Regulus Therapeutics Inc

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.

Organisation	Regulus Therapeutics Inc
E-voting on shares	Click here to vote

FAQs

What is Regulus Therapeutics Inc share price today?

Regulus Therapeutics Inc share price today is $8.18 as on June 25, 2025 at 1:29 am IST at the close of the market. Regulus Therapeutics Inc share today touched a day high of $8.18 and a low of $8.18.

What is the 52 week high and 52 week low for Regulus Therapeutics Inc share?

Regulus Therapeutics Inc share touched a 52 week high of $8.35 on June 9, 2025 and a 52 week low of $0.83 on January 29, 2025. Regulus Therapeutics Inc stock price today i.e. June 25, 2025 at 1:29 am IST is closed at $8.18,which is 1.98% down from its 52 week high and 885.42% up from its 52 week low.

How to invest in Regulus Therapeutics Inc Stock (RGLS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Regulus Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Regulus Therapeutics Inc Shares that will get you 0.1834 shares as per Regulus Therapeutics Inc share price of $8.18 per share as on June 25, 2025 at 1:29 am IST.

What is the minimum amount required to buy Regulus Therapeutics Inc Stock (RGLS) from India?

Indian investors can start investing in Regulus Therapeutics Inc (RGLS) shares with as little as ₹88.27 or $1 (as of September 15, 2025 at 2:33 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹882.70 in Regulus Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 15, 2025 at 2:33 pm IST). Based on Regulus Therapeutics Inc share’s latest price of $8.18 as on June 25, 2025 at 1:29 am IST, you will get 1.2225 shares of Regulus Therapeutics Inc. Learn more about fractional shares .